[Biotech&Pharma] The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

Browse By

Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference.

Biotech stocks closed 2019 with gains, although they underperformed relative to the broader market. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) closed up 25.2% in 2019 compared to the S&P 500's 29% jump.

The new year is likely to bring several challenges for biotech stocks, the chief among them being a hard political stance on drug pricing ahead of the year's elections.

The following are key catalysts that could take the spotlight this week.

Conferences

38th Annual JPMorgan Healthcare Conference: Jan. 13-16 in San Francisco, California.

Adcom Meetings

A joint Tuesday meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss Nektar Therapeutics' (NASDAQ: NKTR) NDA for oxycodegol, a NME …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.